am 251 has been researched along with Anxiety in 52 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Like emotional symptoms such as anxiety, modulations in working memory are among the frequently-reported but controversial psychiatric symptoms associated with nicotine (NC) administration." | 7.79 | Working memory- and anxiety-related behavioral effects of repeated nicotine as a stressor: the role of cannabinoid receptors. ( Hayase, T, 2013) |
| "In the present study, we investigate the effects of the histaminergic system and cannabinoid receptor agents on anxiety-related behaviors and their interactions using the hole-board test on mice." | 7.76 | Anxiety-like behavior induced by histaminergic agents can be prevented by cannabinoidergic WIN55,212-2 injected into the dorsal hippocampus in mice. ( Bina, P; Nasehi, M; Piri, M; Zarrindast, MR, 2010) |
| "Seven days of treatment with CBD reduced mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity." | 5.51 | Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. ( Aboud, M; Comai, S; De Gregorio, D; Enns, J; Gobbi, G; Lopez-Canul, M; Maione, S; McLaughlin, RJ; Ochoa-Sanchez, R; Posa, L, 2019) |
| "AM 251, however, has no anxiolytic effect when the time spent in the center of the OF is considered." | 5.39 | Cannabinoid type 1 receptor ligands WIN 55,212-2 and AM 251 alter anxiety-like behaviors of marmoset monkeys in an open-field test. ( Barros, M; Cagni, P, 2013) |
| "Like emotional symptoms such as anxiety, modulations in working memory are among the frequently-reported but controversial psychiatric symptoms associated with nicotine (NC) administration." | 3.79 | Working memory- and anxiety-related behavioral effects of repeated nicotine as a stressor: the role of cannabinoid receptors. ( Hayase, T, 2013) |
| " In this study we investigated the effects of the eCB anandamide (AEA) and the CB1 antagonist/inverse agonist AM251 infused into the BLA on the acquisition of an aversive memory task, concomitantly evaluating basal anxiety levels in rats." | 3.77 | Pre-training anandamide infusion within the basolateral amygdala impairs plus-maze discriminative avoidance task in rats. ( Barbosa, FF; Cabral, A; Izídio, GS; Leão, AH; Munguba, H; Ribeiro, AM; Silva, RH, 2011) |
| "In the present study, we investigate the effects of the histaminergic system and cannabinoid receptor agents on anxiety-related behaviors and their interactions using the hole-board test on mice." | 3.76 | Anxiety-like behavior induced by histaminergic agents can be prevented by cannabinoidergic WIN55,212-2 injected into the dorsal hippocampus in mice. ( Bina, P; Nasehi, M; Piri, M; Zarrindast, MR, 2010) |
| "A rat model of migraine induced by recurrent administration of nitroglycerin (NTG) (5 mg/kg/i." | 1.62 | The involvement of orexin 1 and cannabinoid 1 receptors within the ventrolateral periaqueductal gray matter in the modulation of migraine-induced anxiety and social behavior deficits of rats. ( Abbasnejad, M; Esmaeili-Mahani, S; Kooshki, R; Pourrahimi, AM; Raoof, M, 2021) |
| " Benzodiazepines can produce rapid effects, but their long-term use may result in severe adverse reaction and drug dependence." | 1.62 | Transcranial direct current stimulation (tDCS) produce anti-anxiety response in acute stress exposure rats via activation of amygdala CB1R. ( Fang, G; Wang, Y, 2021) |
| "Similar to clinical PTSD, approximately 25-30% of rats that undergo cued fear conditioning exhibit impaired extinction learning." | 1.56 | Endocannabinoid modulating drugs improve anxiety but not the expression of conditioned fear in a rodent model of post-traumatic stress disorder. ( Diwan, M; Giacobbe, P; Gidyk, DC; Gouveia, FV; Hamani, C; Lipsman, N; Nobrega, JN; Vimalanathan, A, 2020) |
| "Seven days of treatment with CBD reduced mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity." | 1.51 | Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. ( Aboud, M; Comai, S; De Gregorio, D; Enns, J; Gobbi, G; Lopez-Canul, M; Maione, S; McLaughlin, RJ; Ochoa-Sanchez, R; Posa, L, 2019) |
| " Thus, changes in CB1r function - alone and in combination with cocaine - affected stereotyped vigilance-related behaviors in this NHP, further implicating the eCB system in the neurobiological mechanisms of cocaine addiction." | 1.40 | Cannabinoid type-1 receptor ligands, alone or in combination with cocaine, affect vigilance-related behaviors of marmoset monkeys. ( Barros, M; Cagni, P; de Jesus, AG; Melo, GC, 2014) |
| "AM 251, however, has no anxiolytic effect when the time spent in the center of the OF is considered." | 1.39 | Cannabinoid type 1 receptor ligands WIN 55,212-2 and AM 251 alter anxiety-like behaviors of marmoset monkeys in an open-field test. ( Barros, M; Cagni, P, 2013) |
| "However, RVM inactivation blocked the hyperalgesia produced upon removal from the EPM." | 1.38 | Contribution of the rostral ventromedial medulla to post-anxiety induced hyperalgesia. ( Cornélio, AM; Morgan, MM; Nunes-de-Souza, RL, 2012) |
| ", the compound consistently increased anxiety parameters in all of the three different anxiety tests applied, while a lower dosage of 1mg/kg had no such effect." | 1.35 | Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain. ( Hasenöhrl, RU; Ledent, C; Molleman, A; Thiemann, G; Watt, CA, 2009) |
| "05-5pmol) induced anxiolytic-like effects with bell-shaped dose-response curves, the higher doses being ineffective." | 1.34 | Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. ( Aguiar, DC; Guimarães, FS; Moreira, FA, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (23.08) | 29.6817 |
| 2010's | 34 (65.38) | 24.3611 |
| 2020's | 6 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Pourrahimi, AM | 1 |
| Abbasnejad, M | 1 |
| Raoof, M | 1 |
| Esmaeili-Mahani, S | 1 |
| Kooshki, R | 1 |
| Vimalanathan, A | 1 |
| Gidyk, DC | 1 |
| Diwan, M | 1 |
| Gouveia, FV | 1 |
| Lipsman, N | 1 |
| Giacobbe, P | 1 |
| Nobrega, JN | 1 |
| Hamani, C | 1 |
| Simone, JJ | 4 |
| Baumbach, JL | 2 |
| McPherson, J | 1 |
| McCormick, CM | 4 |
| Fang, G | 1 |
| Wang, Y | 1 |
| Gomes-de-Souza, L | 1 |
| Bianchi, PC | 1 |
| Costa-Ferreira, W | 1 |
| Tomeo, RA | 1 |
| Cruz, FC | 1 |
| Crestani, CC | 1 |
| Batista, LA | 1 |
| de Araújo Moreira, F | 1 |
| Aguiar, DC | 5 |
| Merali, Z | 1 |
| Cayer, C | 1 |
| Kent, P | 1 |
| Liu, R | 1 |
| Cal, V | 1 |
| Harris, CS | 1 |
| Arnason, JT | 1 |
| De Gregorio, D | 1 |
| McLaughlin, RJ | 1 |
| Posa, L | 1 |
| Ochoa-Sanchez, R | 1 |
| Enns, J | 1 |
| Lopez-Canul, M | 1 |
| Aboud, M | 1 |
| Maione, S | 1 |
| Comai, S | 1 |
| Gobbi, G | 1 |
| Szkudlarek, HJ | 1 |
| Desai, SJ | 1 |
| Renard, J | 1 |
| Pereira, B | 1 |
| Norris, C | 1 |
| Jobson, CEL | 1 |
| Rajakumar, N | 1 |
| Allman, BL | 1 |
| Laviolette, SR | 1 |
| Hartmann, A | 1 |
| Fassini, A | 1 |
| Scopinho, A | 1 |
| Correa, FM | 1 |
| Guimarães, FS | 6 |
| Lisboa, SF | 2 |
| Resstel, LB | 3 |
| Ito, S | 1 |
| Deyama, S | 1 |
| Domoto, M | 1 |
| Zhang, T | 1 |
| Sasase, H | 1 |
| Fukao, A | 1 |
| Esaki, H | 1 |
| Hinoi, E | 1 |
| Kaneko, S | 1 |
| Kaneda, K | 1 |
| Tambaro, S | 1 |
| Tomasi, ML | 1 |
| Bortolato, M | 1 |
| Litvin, Y | 1 |
| Phan, A | 1 |
| Hill, MN | 1 |
| Pfaff, DW | 1 |
| McEwen, BS | 1 |
| Almeida-Santos, AF | 1 |
| Gobira, PH | 1 |
| Rosa, LC | 1 |
| Moreira, FA | 4 |
| Magesto, AC | 1 |
| Aguiar, JC | 1 |
| Hajizadeh Moghaddam, A | 1 |
| Bigdellu, R | 1 |
| Fatemi Tabatabaei, SR | 1 |
| Roohbakhsh, A | 3 |
| Cagni, P | 2 |
| Melo, GC | 1 |
| de Jesus, AG | 1 |
| Barros, M | 2 |
| Viana, TG | 1 |
| Hott, SC | 1 |
| Green, MR | 1 |
| Hodges, TE | 1 |
| Fogaça, MV | 2 |
| Sonego, AB | 1 |
| Rioli, V | 1 |
| Gozzo, FC | 1 |
| Dale, CS | 1 |
| Ferro, ES | 1 |
| Qin, M | 1 |
| Zeidler, Z | 1 |
| Moulton, K | 1 |
| Krych, L | 1 |
| Xia, Z | 1 |
| Smith, CB | 1 |
| Malivoire, BL | 1 |
| Tran, S | 1 |
| Chatterjee, D | 1 |
| Facciol, A | 1 |
| Gerlai, R | 1 |
| Geresu, B | 1 |
| Onaivi, E | 1 |
| Engidawork, E | 1 |
| Haj-Mirzaian, A | 2 |
| Amini-Khoei, H | 1 |
| Amiri, S | 1 |
| Ghesmati, M | 1 |
| Zahir, M | 1 |
| Shafaroodi, H | 1 |
| Dehpour, AR | 1 |
| Micale, V | 2 |
| Cristino, L | 2 |
| Tamburella, A | 2 |
| Petrosino, S | 2 |
| Leggio, GM | 2 |
| Drago, F | 2 |
| Di Marzo, V | 2 |
| Thiemann, G | 1 |
| Watt, CA | 1 |
| Ledent, C | 1 |
| Molleman, A | 1 |
| Hasenöhrl, RU | 1 |
| Umathe, SN | 1 |
| Manna, SS | 1 |
| Utturwar, KS | 1 |
| Jain, NS | 1 |
| Keshavarz, S | 1 |
| Hasanein, P | 1 |
| Rezvani, ME | 1 |
| Moghaddam, AH | 2 |
| Zarrindast, MR | 2 |
| Nasehi, M | 1 |
| Piri, M | 1 |
| Bina, P | 1 |
| García-Gutiérrez, MS | 1 |
| Manzanares, J | 1 |
| Sink, KS | 1 |
| Segovia, KN | 1 |
| Sink, J | 1 |
| Randall, PA | 1 |
| Collins, LE | 1 |
| Correa, M | 1 |
| Markus, EJ | 1 |
| Vemuri, VK | 1 |
| Makriyannis, A | 1 |
| Salamone, JD | 1 |
| Seillier, A | 1 |
| Giuffrida, A | 1 |
| Munguba, H | 1 |
| Cabral, A | 1 |
| Leão, AH | 1 |
| Barbosa, FF | 1 |
| Izídio, GS | 1 |
| Ribeiro, AM | 1 |
| Silva, RH | 1 |
| Dono, LM | 1 |
| Currie, PJ | 1 |
| Kupferschmidt, DA | 1 |
| Newman, AE | 1 |
| Boonstra, R | 1 |
| Erb, S | 1 |
| Bialuk, I | 1 |
| Winnicka, MM | 1 |
| Ganon-Elazar, E | 1 |
| Akirav, I | 1 |
| Cornélio, AM | 1 |
| Nunes-de-Souza, RL | 1 |
| Morgan, MM | 1 |
| Aydin, C | 1 |
| Oztan, O | 1 |
| Isgor, C | 1 |
| Hayase, T | 1 |
| Rodgers, RJ | 1 |
| Evans, PM | 1 |
| Murphy, A | 1 |
| Massoudi, R | 1 |
| Pandolfo, P | 1 |
| Pamplona, FA | 1 |
| Prediger, RD | 1 |
| Takahashi, RN | 1 |
| Haller, J | 1 |
| Mátyás, F | 1 |
| Soproni, K | 1 |
| Varga, B | 1 |
| Barsy, B | 1 |
| Németh, B | 1 |
| Mikics, E | 1 |
| Freund, TF | 1 |
| Hájos, N | 1 |
| Rubino, T | 1 |
| Guidali, C | 1 |
| Vigano, D | 1 |
| Realini, N | 1 |
| Valenti, M | 1 |
| Massi, P | 1 |
| Parolaro, D | 1 |
| Naderi, N | 1 |
| Haghparast, A | 1 |
| Saber-Tehrani, A | 1 |
| Rezaii, N | 1 |
| Alizadeh, AM | 1 |
| Khani, A | 1 |
| Motamedi, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Dose Controlled Diabetic Neuropathic Pain Study Using Non-Intoxicating Cannabidiol in a Rapidly Dissolvable Sublingual Tablet[NCT04088929] | Phase 2 | 32 participants (Actual) | Interventional | 2019-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet[NCT04679545] | Phase 2 | 50 participants (Anticipated) | Interventional | 2020-12-10 | Recruiting | ||
| Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury[NCT04057456] | Phase 3 | 140 participants (Anticipated) | Interventional | 2023-03-01 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol and Palmitoylethanolamide for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet[NCT05766969] | Phase 1/Phase 2 | 52 participants (Anticipated) | Interventional | 2023-06-05 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
52 other studies available for am 251 and Anxiety
| Article | Year |
|---|---|
The involvement of orexin 1 and cannabinoid 1 receptors within the ventrolateral periaqueductal gray matter in the modulation of migraine-induced anxiety and social behavior deficits of rats.
Topics: Animals; Anxiety; Behavior, Animal; Benzoxazoles; Male; Migraine Disorders; Naphthyridines; Orexin R | 2021 |
Endocannabinoid modulating drugs improve anxiety but not the expression of conditioned fear in a rodent model of post-traumatic stress disorder.
Topics: Animals; Anxiety; Benzamides; Benzoxazines; Carbamates; Conditioning, Psychological; Disease Models, | 2020 |
Adolescent CB1 receptor antagonism influences subsequent social interactions and neural activity in female rats.
Topics: Animals; Anxiety; Brain Chemistry; Early Growth Response Protein 1; Endocannabinoids; Female; Male; | 2020 |
Transcranial direct current stimulation (tDCS) produce anti-anxiety response in acute stress exposure rats via activation of amygdala CB1R.
Topics: Amygdala; Animals; Anxiety; Behavior, Animal; Disease Models, Animal; Male; Piperidines; Pyrazoles; | 2021 |
CB
Topics: Animals; Anxiety; Cannabinoid Receptor Antagonists; Dioxoles; Endocannabinoids; Gene Expression; Mal | 2021 |
Interactions between the nitrergic and the endocannabinoid system in rats exposed to the elevated T-maze.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Disease Models, Animal; Endocannabinoids; L | 2021 |
Sacred Maya incense, copal (Protium copal - Burseraceae), has antianxiety effects in animal models.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Burseraceae; Carrier Proteins; Ceremonial B | 2018 |
Sex-specific effects of CB1 receptor antagonism and stress in adolescence on anxiety, corticosterone concentrations, and contextual fear in adulthood in rats.
Topics: Aging; Animals; Anxiety; Body Weight; Brain Chemistry; Corticosterone; Emotions; Endocannabinoids; E | 2018 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Δ-9-Tetrahydrocannabinol and Cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors.
Topics: Affect; Animals; Anxiety; Behavior, Animal; Benzopyrans; Cannabidiol; Dizocilpine Maleate; Dose-Resp | 2019 |
Role of the endocannabinoid system in the dorsal hippocampus in the cardiovascular changes and delayed anxiety-like effect induced by acute restraint stress in rats.
Topics: Amidohydrolases; Animals; Anxiety; Arachidonic Acids; Arterial Pressure; Behavior, Animal; Benzamide | 2019 |
Effects of the synthetic cannabinoid 5F-AMB on anxiety and recognition memory in mice.
Topics: Animals; Anxiety; Cannabinoids; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Piperidines; Prefr | 2019 |
Long-term CB₁ receptor blockade enhances vulnerability to anxiogenic-like effects of cannabinoids.
Topics: Animals; Anxiety; Behavior, Animal; Brain; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antag | 2013 |
CB1 receptor signaling regulates social anxiety and memory.
Topics: Adaptation, Psychological; Animals; Anxiety; Arousal; Freezing Reaction, Cataleptic; Male; Memory; M | 2013 |
Modulation of anxiety-like behavior by the endocannabinoid 2-arachidonoylglycerol (2-AG) in the dorsolateral periaqueductal gray.
Topics: Analysis of Variance; Animals; Anxiety; Arachidonic Acids; Biphenyl Compounds; Cannabinoid Receptor | 2013 |
Complex interaction between anandamide and the nitrergic system in the dorsolateral periaqueductal gray to modulate anxiety-like behavior in rats.
Topics: Animals; Anxiety; Apomorphine; Arachidonic Acids; Bicuculline; Cannabinoid Receptor Agonists; Diseas | 2013 |
Cannabinoid system of the lateral septum in the modulation of anxiety-like behaviors in rats.
Topics: Animals; Anxiety; Behavior, Animal; Benzoxazines; Cannabinoid Receptor Agonists; Cannabinoid Recepto | 2013 |
Cannabinoid type-1 receptor ligands, alone or in combination with cocaine, affect vigilance-related behaviors of marmoset monkeys.
Topics: Analysis of Variance; Animals; Anxiety; Benzoxazines; Calcium Channel Blockers; Callithrix; Cocaine; | 2014 |
Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attacks in rats.
Topics: Amidohydrolases; Animals; Anxiety; Arachidonic Acids; Behavior, Animal; Benzamides; Carbamates; Dise | 2015 |
Differential effects of CB1 receptor agonism in behavioural tests of unconditioned and conditioned fear in adult male rats.
Topics: Animals; Anxiety; Arachidonic Acids; Conditioning, Psychological; Corticosterone; Extinction, Psycho | 2015 |
Anxiogenic-like effects induced by hemopressin in rats.
Topics: Anilides; Animals; Anxiety; Brain; Capsaicin; Cinnamates; Hemoglobins; Injections, Intraventricular; | 2015 |
Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome.
Topics: Amidohydrolases; Animals; Anxiety; Arachidonic Acids; Avoidance Learning; Benzamides; Cannabinoid Re | 2015 |
Effects of CB1 receptor agonism and antagonism on behavioral fear and physiological stress responses in adult intact, ovariectomized, and estradiol-replaced female rats.
Topics: Animals; Anxiety; Arachidonic Acids; Conditioning, Classical; Corticosterone; Estradiol; Extinction, | 2015 |
Concentration, population, and context-dependent effects of AM251 in zebrafish.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anxiety; Brain; Dopamine; Dose-Response Relationship, Drug; | 2016 |
Behavioral evidence for the interaction between cannabinoids and Catha edulis F. (Khat) in mice.
Topics: Animals; Anxiety; Behavior, Animal; Benzoxazines; Cannabinoid Receptor Agonists; Catha; Endocannabin | 2016 |
Activation of cannabinoid receptors elicits antidepressant-like effects in a mouse model of social isolation stress.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzoxazines; Cannabinoid Receptor Agonis | 2017 |
Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels.
Topics: Amidohydrolases; Anilides; Animals; Anti-Anxiety Agents; Anxiety; Arachidonic Acids; Benzamides; Bra | 2009 |
Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain.
Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Biogenic Amines; Brain Chemistry; Disease | 2009 |
Endocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors.
Topics: Acetaminophen; Animals; Anti-Anxiety Agents; Anxiety; Arachidonic Acids; Behavior, Animal; Cannabino | 2009 |
Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anti-Inflammatory Agents, Non-Steroidal; Anxiety | 2009 |
Role of endocannabinoid system in the ventral hippocampus of rats in the modulation of anxiety-like behaviours.
Topics: Amidohydrolases; Animals; Anxiety; Baclofen; Behavior, Animal; Benzamides; Bicuculline; Cannabinoid | 2009 |
Anxiety-like behavior induced by histaminergic agents can be prevented by cannabinoidergic WIN55,212-2 injected into the dorsal hippocampus in mice.
Topics: Animals; Anxiety; Benzoxazines; Exploratory Behavior; Hippocampus; Histamine; Histamine Antagonists; | 2010 |
The cannabinoid CB1 receptor is involved in the anxiolytic, sedative and amnesic actions of benzodiazepines.
Topics: Alprazolam; Amnesia; Amygdala; Animals; Anti-Anxiety Agents; Anxiety; Avoidance Learning; Behavior, | 2010 |
Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142.
Topics: Animals; Anxiety; Brain; Carbolines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug | 2010 |
Inhibition of fatty acid amide hydrolase modulates anxiety-like behavior in PCP-treated rats.
Topics: Amidohydrolases; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Benzamides; Carbamates; En | 2011 |
Pre-training anandamide infusion within the basolateral amygdala impairs plus-maze discriminative avoidance task in rats.
Topics: Amygdala; Analysis of Variance; Animals; Anxiety; Arachidonic Acids; Avoidance Learning; Cannabinoid | 2011 |
The cannabinoid receptor CB₁ inverse agonist AM251 potentiates the anxiogenic activity of urocortin I in the basolateral amygdala.
Topics: Amygdala; Animals; Anti-Anxiety Agents; Anxiety; Disease Models, Animal; Dose-Response Relationship, | 2012 |
Antagonism of cannabinoid 1 receptors reverses the anxiety-like behavior induced by central injections of corticotropin-releasing factor and cocaine withdrawal.
Topics: Animals; Anxiety; Behavior, Animal; Cocaine; Corticosterone; Corticotropin-Releasing Hormone; Dopami | 2012 |
AM251, cannabinoids receptors ligand, improves recognition memory in rats.
Topics: Animals; Anxiety; Dose-Response Relationship, Drug; Male; Maze Learning; Motor Activity; Piperidines | 2011 |
Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress.
Topics: Amygdala; Animals; Anxiety; Avoidance Learning; Benzoxazines; Cannabinoid Receptor Agonists; Cannabi | 2012 |
Contribution of the rostral ventromedial medulla to post-anxiety induced hyperalgesia.
Topics: Animals; Anxiety; GABA-A Receptor Agonists; Hyperalgesia; Male; Medulla Oblongata; Muscimol; Pain Me | 2012 |
The endocannabinoid and endovanilloid systems interact in the rat prelimbic medial prefrontal cortex to control anxiety-like behavior.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Arachidonic Acids; Behavior, Animal; Capsaicin; Endocannabino | 2012 |
Nicotine-induced anxiety-like behavior in a rat model of the novelty-seeking phenotype is associated with long-lasting neuropeptidergic and neuroplastic adaptations in the amygdala: effects of the cannabinoid receptor 1 antagonist AM251.
Topics: Aging; Amygdala; Animals; Anxiety; Brain-Derived Neurotrophic Factor; Corticotropin-Releasing Hormon | 2012 |
Cannabinoid type 1 receptor ligands WIN 55,212-2 and AM 251 alter anxiety-like behaviors of marmoset monkeys in an open-field test.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Benzoxazines; Callithrix; Cannabinoid Recep | 2013 |
Working memory- and anxiety-related behavioral effects of repeated nicotine as a stressor: the role of cannabinoid receptors.
Topics: Analysis of Variance; Animals; Anxiety; Brain; Disease Models, Animal; Dose-Response Relationship, D | 2013 |
Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice.
Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Dose-Response Relationship, Drug; Male; Ma | 2005 |
Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray.
Topics: Animals; Anxiety; Arachidonic Acids; Behavior, Animal; Cannabinoids; Disease Models, Animal; Dose-Re | 2007 |
Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test.
Topics: Analgesics; Animals; Anxiety; Arginine; Benzoxazines; Cannabinoids; Enzyme Inhibitors; Hippocampus; | 2007 |
Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55,212-2.
Topics: Aging; Animals; Anxiety; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Benzoxazin | 2007 |
Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission.
Topics: Analgesics; Animals; Anti-Anxiety Agents; Anxiety; Benzoxazines; Cannabinoids; Chlordiazepoxide; Exc | 2007 |
CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour.
Topics: Amygdala; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Anxiety; Behavior, Animal; Brain; | 2008 |
Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice.
Topics: Amidohydrolases; Animals; Anxiety; Arachidonic Acids; Behavior, Animal; Benzamides; Benzoxazines; Ca | 2008 |